CellFE, a leader in non-viral gene editing technology, announces a strategic collaboration with the Harbottle Lab at German Cancer Research Center (DKFZ) and its spin-out company, TcellTech.
CellFE announced today an upcoming presentation by CEO Alla Zamarayeva, PhD, at the International Society of Gene & Cell Therapy (ISCT) Annual Meeting, taking place May 29-June 1, 2024 in Vancouver, BC.
CellFE announced today an upcoming presentation by CSO Todd Sulchek, PhD, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 7-11, 2024 in Baltimore, MD.
CellFE will be presenting two posters at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting next week occurring from May 11-14.
CellFE will be presenting a poster at the International Society of Gene and Cell Therapy (ISCT) Annual Meeting next week with a poster on Transfecting αβ T Cells with CRISPR-Cas9 RNP via microlfuidic method.
Managing toxicity and specificity of cell therapies relies on complex gene-editing mechanisms, requiring co-delivery of multiple gene-editing molecules.
